|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.460 USD | +2.67% |
|
+5.49% | -63.11% |
| 07-06 | Alvotech Faces 'Soft' Q2 but Well Positioned to Benefit From Upcoming Biosimilar Opportunity, UBS Says | MT |
| 07-01 | Alvotech announced that it has received $175 million in funding | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 49.18B | |||||
| 39.58B | - | - | - | - | - |
| 34.69B | |||||
| 34.42B | |||||
| 27.11B |
- Stock Market
- Stocks
- ALVO Stock
- ALVO Stock
- Charts Alvotech
- Sector Chart
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
